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Jeanette Wagener1,10, Josef J. Schneider2,10, Susann Baxmann3,10, Hubert Kalbacher4, Claudia Borelli2,
Sabine Nuding5, Robert Ku¨chler5, Jan Wehkamp5, Matthias D. Kaeser6, Daniela Maila¨nder-Sanchez1,
Christina Braunsdorf1, Bernhard Hube7,8,9, Lydia Schild7, Wolf-Georg Forssmann3, Hans-Christian Korting2,
Cornelia Liepke3 and Martin Schaller1
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) has an important role not only in glycolysis but also in
nonmetabolic processes, including transcription activation and apoptosis. We report the isolation of a human
GAPDH (hGAPDH) (2-32) fragment peptide from human placental tissue exhibiting antimicrobial activity. The
peptide was internalized by cells of the pathogenic yeast Candida albicans and initiated a rapid apoptotic
mechanism, leading to killing of the fungus. Killing was dose-dependent, with 10 mgml (3.1 mM) and 100 mgml
hGAPDH (2-32) depolarizing 45% and 90% of the fungal cells in a population, respectively. Experimental C.
albicans infection induced epithelial hGAPDH (2-32) expression. Addition of the peptide significantly reduced
the tissue damage as compared with untreated experimental infection. Secreted aspartic proteinase (Sap)
activity of C. albicans was inhibited by the fragment at higher concentrations, with a median effective dose of
160mg l1 (50 mM) for Sap1p and 200mg l1 (63 mM) for Sap2p, whereas Sap3 was not inhibited at all. Interestingly,
hGAPDH (2-32) induced significant epithelial IL-8 and GM-CSF secretion and stimulated Toll-like receptor 4
expression at low concentrations independently of the presence of C. albicans, without any toxic mucosal
effects. In the future, the combination of different antifungal strategies, e.g., a conventional fungicidal with
immunomodulatory effects and the inhibition of fungal virulence factors, might be a promising treatment option.
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INTRODUCTION
Owing to the increased number of immunosuppressed patients
resulting from AIDS, organ transplants, and drug addiction,
the frequency of fungal infections with the opportunistic
yeast Candida albicans has risen (Leroy et al., 2009). These
infections, especially oropharyngeal candidiasis, are widely
treated with fluconazole. The long-term treatment with azoles
has led to the emergence of azole-resistant strains of C.
albicans (Fera et al., 2009). Azoles inhibit the key enzyme of
ergosterol biosynthesis, cytochrome P-450-dependent lanos-
terol-14a-demethylase. Known mechanisms of azole resis-
tance are the decreased availability of lanosterol-14a-
demethylase and efflux pumps (Peman et al., 2009; Sanglard
et al., 2009).
Another therapeutic option is to affect fungal virulence
factors, such as secreted hydrolytic enzymes, yeast-to-hyphal
transition, adhesion factors, phenotypic switching, thigmo-
tropism, and molecular mimicry. During the last decade,
secreted aspartic proteinase (Sap) activity has been char-
acterized as one of the major virulence factors of C. albicans
(Schaller et al., 2005). Ten SAP genes have been identified
in C. albicans. The corresponding proteinases are crucial
for distinct steps in pathogenesis, such as adhesion and
penetration. The interest in Sap inhibitors started with the
treatment of AIDS patients with highly active antiretroviral
therapy, a combination of HIV aspartic proteinase and
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reverse transcriptase inhibitors. Some of the clinically used
HIV proteinase inhibitors, e.g., saquinavir and indinavir,
also have the ability to inhibit Sap activity and therefore may
prevent fungal infections or reduce their severity (Korting
et al., 1999). This finding led to an enhanced effort of
focusing research on specific Sap inhibitors by solving the X-
ray crystal structures of these proteinases and by the
development of Sap-specific inhibitors (Borelli et al., 2008;
Braga-Silva and Santos, 2011). Most HIV aspartic proteinase
inhibitors and Sap inhibitors are short peptide-like ligands
mimicking substrates for HIV proteinase (Gauwerky et al., 2009).
Moreover, it has been shown that lysozyme (muramidase),
an antimicrobial peptide effective against a wide range of
bacteria, not only inhibited the growth of C. albicans but also
decreased the secretion of the isoenzyme Sap2, which is the
predominant secreted isoenzyme (Wu et al., 1999).
In the present investigation, we examined the effect of an
antimicrobial peptide, purified from human placental tissue,
on the growth of C. albicans, and on Sap activity. In addition,
we analyzed the protective and immunomodulatory effects
during epithelial infection.
RESULTS
Purification of hGAPDH (2-32) from human placental tissue
A peptide library orginating from human placental tissue was
initially screened for growth inhibition against E. coli using a
radial diffusion assay. Antimicrobial activity was detected in
several HPLC fractions of pH pool 4. Of this pool, the
fractions 19 and 20, which exhibited the highest growth-
inhibitory activity, were selected for further purification
(Figure 1a). To isolate the active compounds, two subsequent
HPLC steps were carried out, tracking the maximum antimi-
crobial activity within the resulting fractions. The antimicro-
bial active fractions were loaded onto a reversed-phase
column. Elution of bound material was carried out by linearly
increasing the amount of solvent B. Growth-inhibitory
activity was eluted over a broad range, and antibacterial
fractions were selected for further purification. As it is known
that most antimicrobial peptides are of a cationic nature, a
strong cation-exchange column was used for final purifica-
tion. The resulting three HPLC fractions showing the strongest
antimicrobial activity (Figure 1b) were desalted and subse-
quently tested for further analyses (Figure 1c). Analysis of
HPLC fraction 23 by capillary zone electrophoresis revealed
a compound of high purity (data not shown).
The molecular mass of the purified peptide was deter-
mined to be 3,188 Da measured by matrix-assisted laser
desorption/ionization mass spectrometry (Figure 1d).
Edman degradation yielded the following peptide se-
quence of 31 amino-acid residues: GKVKVGVNGFGRIGRL
VTRAAFNSGKVDIVA. Comparison of the amino-acid se-
quence obtained with the SwissProt Database showed 100%
identity with the N-terminal fragment of the human protein
glyceraldehyde-3-phosphate dehydrogenase (Figure 1e).
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Figure 1. Purification of the antimicrobial peptide human glyceraldehyde-3-phosphate dehydrogenase (hGAPDH) (2-32) from human placental tissue. Each
purification step was monitored by radial diffusion assay for detection of antimicrobial activity. (a) The bars show the diameters of inhibition zones indicating
the antimicrobial activity against E. coli. Fractions 19 and 20, corresponding to the maximum growth inhibition, were selected for further purification.
(b) Fractions 19 and 20 were pooled and fractionated by reversed-phase (RP) chromatography. Final purification of the antimicrobial peptide was performed,
(b) separating fraction 23 (c) using a strong cation-exchange column. (d) Matrix-assisted laser desorption/ionization mass spectrometry analysis of the
purified peptide revealed a molecular mass of 3,188 Da. Sequence analysis led to the identification of an N-terminal fragment of GAPDH. (e) Amino-acid
sequence is shown in the single-letter code. MW, molecular weight.
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Functional characterization of the synthetic antimicrobial
peptide
Antimicrobial activity. To analyze the identity and biological
properties of the isolated peptide, human glyceraldehyde-3-
phosphate dehydrogenase (hGAPDH) (2-32) was chemically
synthesized. To specify the spectrum of activity of the
peptide, its antimicrobial activity was determined by a flow
cytometric antimicrobial killing assay (Nuding et al., 2006).
This assay demonstrated a potent antibacterial activity of this
peptide against E. coli (Figure 2a) and confirmed the results of
the radial diffusion assay, which was originally used to screen
the HPLC fractions for growth-inhibitory activity against this
Gram-negative bacterium (Figure 1c). Two of the four tested
C. albicans strains were similarly highly susceptible to the
hGAPDH (2-32) fragment, with 10 mg ml1 depolarizing
B50% of the fungi in a population, whereas two other
strains showed a slightly lower sensitivity (Figure 2a). We
compared the activity spectrum of our peptide with that of LL-
37 and human b-defensin-3 (hBD-3). The antifungal
activities of all three peptides against C. albicans were not
significantly different, whereas hGAPDH (2-32) was less
active against E. coli. The antifungal effect of h(GAPDH)
2-32 was dose dependent, as shown for C. albicans SC5314
(Figure 2b).
The antimicrobial activity was also confirmed by the broth
microdilution method (minimal inhibitory concentration
100%) against several bacterial strains and C. albicans. The
identified peptide exhibited a broad spectrum of activity,
inhibiting the growth of Gram-negative bacteria (E. coli BL21,
Pseudomonas aeruginosa (P. aeruginosa) PAO, P. aeruginosa
clinical isolate) and C. albicans in micromolar concentrations
(data not shown).
Ultrastructural changes of C. albicans morphology induced
by hGAPDH (2-32). Whereas untreated C. albicans SC5314
cells were in a uniform physiological state (Figure 2c),
incubation of yeasts with hGAPDH (2-32) in a concentration
of 125mg ml1 for 24 hours resulted in distinct changes of the
cell wall, plasma membrane, and the cytoplasm (Figure 2d).
Morphological alterations included enlargement of the fungal
cytoplasmic vacuoles, disorganization of the internal orga-
nelles, and the appearance of yeasts with an empty cytoplasm
resembling necrotic ghost cells.
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Figure 2. Antimicrobial killing assays and electron microscopy. (a) Flow cytometric antimicrobial killing assay of E. coli and Candida albicans (C. albicans)
incubated with 10 mg ml1 human glyceraldehyde-3-phosphate dehydrogenase (hGAPDH) (2-32), LL-37, or human b-defensin-3 (hBD-3). Dose-dependent
effect of hGAPDH (2-32). Suspensions of C. albicans were incubated with hGAPDH (2-32) for 90 minutes. (b) The antimicrobial activity is shown as
percentage of depolarized microorganisms. The data are means of one representative experiment in triplicate. Electron microscopy of C. albicans SC5314
cells grown (c) without and (d) with 125mg ml1 hGAPDH (2-32) for 24 hours. (c) Cells grown without hGAPDH (2-32) with a regular morphology.
(d) C. albicans grown under the influence of hGAPDH (2-32) shows enlargement of cytoplasmic vacuoles and disorganization of the internal organelles.
Bar¼500 nm.
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Inhibition of Sap activity. Addressing the question of
whether hGAPDH (2-32) has an inhibitory activity against
C. albicans Sap, we tested inhibition of the recombinant
proteins Sap1, 2, and 3. The Sap-specific test showed an ED50
(median effective dose) of 160 mg ml1 (50 mM) for Sap1p and
200mg ml1 (63 mM) for Sap2p, whereas Sap3 was not
inhibited (Figure 3).
Experimental C. albicans infection. We used epithelial
monolayers of the TR146 cell line to analyze the antimicro-
bial effect of hGAPDH (2-32) during infection. LDH values
12 and 24 hours after infection with C. albicans SC5314 were
significantly decreased even in the presence of the lowest
hGAPDH (2-32) concentration of 5 mg ml1 as compared with
untreated controls (Figure 4a). The protective effect of
hGAPDH (2-32) was similar to that of LL-37. Treatment of
uninfected epithelial cells with hGAPDH (2-32) also demon-
strated that this peptide has low toxicity on mammalian cells
(Figure 4a). Analyses of standard LDH samples in the absence
and presence of 5 and 125mg ml1 hGAPDH (2-32) excluded
inhibition of the LDH enzymatic assay by the antimicrobial
peptide. We also demonstrated that LDH is exclusively
secreted by the epithelial cells and not by C. albicans cells
(data not shown).
Histological examination of reconstituted human oral
epithelium (RHE), which consists of differentiated multilayers
of the TR146 cell line taken 18 hours after infection with C.
albicans SC5314, demonstrated clusters of fungal cells on the
superficial keratinocytes and prominent lesions with edema
and vacuolization of the keratinocytes and enlarged inter-
cellular spaces as a sign of spongiosis. C. albicans effectively
invaded all keratinocyte layers of the oral epithelium,
affecting the tissue with a high number of microorganisms
(Figure 4b). In contrast, histological examination of infected
samples treated with 125 mg ml1 hGAPDH (2-32) demon-
strated far less marked morphological alterations. Spongiosis
and invasion of keratinocytes by yeast cells were inhibited by
hGAPDH (2-32), only the formation of mild edema in the
uppermost keratinocyte layers resulted from Candida infec-
tion. In accordance with the minor tissue lesions observed,
the number of yeast cells on the mucosal surface was
decreased (Figure 4c).
We used an anti-hGAPDH (2-32) antiserum raised in
rabbits to carry out immunofluorescence in our RHE model
by confocal laser microspcopy. The specificity of the
generated antibody against hGAPDH (2-32) was verified by
ELISA, demonstrating a signal against the hGAPDH (2-32)
peptide but no signal against the hGAPDH protein. The
specificity of our antibody was further confirmed in our RHE
experiments by staining of the peptide only in the hGAPDH
(2-32)-treated (Figure 4e and g) and/or C. albicans–infected
samples (Figure 4f and g) but not in the untreated and
uninfected RHE (Figure 4d). Confocal laser scanning micro-
scopy showed increased endogenous expression of hGAPDH
(2-32) during RHE infection (Figure 4f), whereas no evidence
for staining was seen in the uninfected phosphate-buffered
saline (PBS) control (Figure 4d). In addition, we were able to
demonstrate a strong affinity of the external but also of the
endogenous peptide to C. albicans and internalization by the
fungal cells (Figure 4f and g higher magnifications).
Apoptosis and necrosis of C. albicans in the presence of
hGAPDH (2-32). Several reports about apoptotic cell death
induced by antimicrobial peptides prompted us to investigate
whether an apoptosis-like process occurs in hGAPDH (2-32)-
treated C. albicans cells. Cells dying under these conditions
display several markers characteristic of apoptosis. These
include the rapid exposure of phosphatidylserine, detectable
at the outer cell membrane by annexin V–FITC staining. In our
assay, apoptotic and necrotic cells were distinguished by double
staining for annexin V-FITC (green) and propidium iodide,
which is a membrane-impermeant DNA fluorescent stain
(Figure 5). Cells exposed to 5mg ml1 hGAPDH (2-32) for
1 hour (Figure 5c and e) showed peripheral fluorescence in 31%
of the protoplasts. C. albicans cells treated for a longer time with
this concentration or at higher doses of these compounds
showed cellular changes characteristic of necrosis (Figure 2d).
Annexin V–FITC-stained cells were observed only rarely in
control assays performed without peptide (Figure 5a and b).
Immunomodulatory activity of hGAPDH (2-32). We inves-
tigated the role of hGAPDH (2-32) in initiating an epithelial
chemokine response. Protein secretion and gene expression
were quantified in the presence and absence of C. albicans
SC5314 and 5mg ml1 hGAPDH (2-32) by use of ELISA and
real-time reverse transcriptase–PCR. In response to C. albicans,
epithelial cells secreted significantly increased amounts of IL-8
and GM-CSF (Figure 6a), which is in line with our previous
studies (Weindl et al., 2007). Surprisingly, hGAPDH (2-32)
also induced increased secretion of GM-CSF and IL-8 of
uninfected epithelial. IL-8 was increased even after C. albicans
infection (Figure 6a and b). A similar stimulation pattern was
also observed for epithelial Toll-like receptor 4 (TLR4) mRNA
expression (Figure 6c).
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Figure 3. Human glyceraldehyde-3-phosphate dehydrogenase (hGAPDH)
(2-32) inhibits the activity of secreted aspartic proteinases (Saps), virulence
attributes of Candida albicans (C. albicans). Specific inhibition of Sap1-3
showed an ED50 (median effective dose) of 160 mg ml
1 (50 mM) for Sap1p and
200mg ml1 (63 mM) for Sap2p, while Sap3p was not inhibited. Error bars
indicate range of duplicates. Each duplicate consists of three background-
normalized measures.
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Extensive studies ruled out any effects of possible
contamination with lipopolysaccharide (o100 pg ml1).
These data thus indicate that hGAPDH (2-32) possesses
immune stimulatory activity that might contribute to the
protective effect.
DISCUSSION
With the aim of identifying naturally occurring antimicrobial
active peptides in humans, we established a peptide library
from human placental tissue as a known source for low-
molecular-mass antimicrobial components. Purification pro-
cedures led to the isolation of a GAPDH-derived peptide with
antibacterial and anticandidal properties. Although its glyco-
lytic function, the conversion of D-glyceraldehyde-3-phos-
phate to 1,3-bisphosphoglycerate, is well known, recent
evidence suggests that this highly versatile molecule has
several diverse roles in living systems. Mammalian GAPDH is
involved in membrane fusion (Morero et al., 1985), vesicle
transport (Tisdale, 2001), microtubule bundling (Sirover,
1999), phosphotransferase activity, nuclear RNA export
(Singh and Green, 1993), prostate cancer progression,
programmed cell death, DNA replication, and DNA repair
(Sirover, 1999, 2011). This came as a surprise to researchers,
but it makes evolutionary sense to reuse and adapt an existing
protein instead of evolving a novel protein from scratch.
It also makes sense that a GAPDH fragment acts as an
antimicrobial peptide, because GAPDH is widely expressed
in a multitude of tissues (Barber et al., 2005) and is found
not only intracellularly but also extracellularly (Yamaji
et al., 2005). Cell injury by invading pathogens might
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Figure 4. Experimental Candida albicans (C. albicans) infection. Release of lactase dehydrogenase (LDH) by monolayer epithelial cells 12 hours after
infection (or not) with C. albicans in the presence and absence of 5 mg ml1 LL-37 or human glyceraldehyde-3-phosphate dehydrogenase (hGAPDH) (2-32).
Multiplicity of infection: 0.1. (a) Epithelial cells were preincubated with the peptide for 1 hour. Statistical significance was determined using the two-tailed
paired Student’s t test (n¼6). Light micrographs of reconstituted human oral epithelium (RHE) 18 hours after infection with C. albicans SC5314 in the absence
and presence of hGAPDH (2-32). (b) Invasion by C. albicans of all epithelial layers, with extensive edema and vacuolization in the absence of hGAPDH (2-32).
Strongly reduced virulence phenotype resulting in a protective effect in the presence of hGAPDH (2-32). (c) Decreased number of C. albicans cells. Confocal
laser microscopy of oral RHE after 12 hours in the presence and absence of C. albicans and 5 mg ml1 hGAPDH (2-32) (cell nuclei, green; hGAPDH (2-32),
red; C. albicans, blue). (d) No evidence for hGAPDH (2-32) in the uninfected and untreated oral RHE. (e) The presence of hGAPDH (2-32) on the superficial
layers of the uninfected RHE after external addition. (f) Increased expression in the C. albicans–infected but untreated oral RHE. (f, g) Strong affinity of the
peptide to the C. albicans cells after external addition of hGAPDH (2-32). Higher-magnification image demonstrating direct contact of the peptide with
C. albicans cells (short arrow) and internalization by the fungal cells (long arrow). Bar¼30 mm. **Po0.01, IL-37 and hGAPDH.
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even enlarge this extracellular fraction, and proteolytic
degradation of GAPDH by the pathogen or the host might
lead to the generation of smaller peptides with antimicro-
bial activity. Most recently, a role of microbial GAPDH in
virulence has been postulated (Egea et al., 2007; Dumke
et al., 2011). Moreover, evidence has been shown that
GAPDH is relevant for the functioning of cationic host
defense peptides as a mononuclear cell receptor for
human cathelicidin LL-37 and immunomodulatory IDR-1
(Mookherjee et al., 2009).
The isolated peptide exhibits antimicrobial activity
against E. coli and C. albicans in micromolar concentra-
tions. It is very difficult to compare the antifungal activity of
hGAPDH (2-32) in our experiments with those of the
peptides described earlier in the literature, because it is
well known that their activity is highly reliant on the
conditions used to test antifungal activity. We therefore
used the depolarization assay described in this paper to
compare the antifungal activity of hGAPDH (2-32) with
those of LL-37 and hBD3. The antifungal activities of all
three peptides against C. albicans were not significantly
different, whereas hGAPDH (2-32) was less active against
E. coli. The relevance of our peptide as an antifungal
peptide is confirmed by the observation that antifungal
activity was also demonstrated in different media by
the radial diffusion test and microdilution broth method.
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In addition, we found a protective effect during C. albicans
infection of epithelial monolayers and multilayers compar-
able to the effect of LL-37 but independently from the
culture media conditions.
The morphological changes observed in hGAPDH (2-32)-
treated C. albicans cells are related mainly to cytoplasm and
the organelles, suggesting internalization of the peptide. We
were able to confirm cellular uptake after binding of the
peptide to the cell wall of the fungi by immunofluorescence
microscopy. The induction of apoptosis by hGAPDH (2-32)
was characterized as a major killing mechanism by the
exposure of phosphatidylserine from the inner to outer
surface of the membrane as a representative hallmark of
early-stage apoptosis.
The ongoing spread of antimycotic resistance is seriously
undermining the present alternatives for therapeutic inter-
vention against human candidiasis. Therefore, it becomes
important to search and develop targets for antimicrobial
therapy. Over the past few decades, the search for drugs and
drug targets has prompted an interest in antimicrobial
peptides. These are important components of the innate
immune system, used by the host to protect itself from
different types of pathogenic microorganisms. Besides their
direct effects on microbial cells, there is a growing body of
evidence that mammalian antimicrobial peptides directly
influence host cells, thereby inducing several mechanisms of
the inflammatory processes and an immune response to the
invading pathogens (Schittek et al., 2008). In this study, we
suggest a role of antimicrobial peptides during host–pathogen
interaction by inhibition of aspartic proteinases secreted by
C. albicans. The production of these Sap by C. albicans is a
putative virulence attribute of these opportunistic yeasts (Zhu
and Filler, 2010). Preincubation of epithelial cells with the
proteinase inhibitor pepstatin A before C. albicans infection
significantly reduced invasion compared with untreated cells
(Dalle et al., 2010). Experiments using triple mutants, lacking
Sap1-3, confirmed the role of these isoenzymes for induced
endocytosis (Dalle et al., 2010). An ED50 of 160 mg ml
1 or
50 mM hGAPDH (2-32) for Sap1p and 200mg ml1 or 63 mM
for Sap2p suggests that inhibition of these important virulence
factors only partially contributes to epithelial protection in
our experiments. A more significant role of this peptide as
a Sap inhibitor in vivo cannot be excluded, as GAPDH is
widely expressed and abundantly present in a multitude
of tissues, especially after epithelial injury during mucosal
infection.
The outlook for the effectiveness of therapeutic
approaches combining inhibitory effects on the growth
and against virulence factors of C. albicans appears quite
favorable. Lysozyme is an antimicrobial protein ubiquitous in
human mucosal secretions such as saliva and effective
against a wide range of bacteria. In a previous study, it has
been shown that lysozyme has a bimodal action on
C. albicans, killing the organism at higher concentrations
and decreasing the production of Sap at lower concentrations
(Wu et al., 1999).
The peptide hGAPDH (2-32) is secreted by oral epithelial
cells during C. albicans infection, suggesting that this
antimicrobial peptide serves as a host defense substance also
in vivo.
We also determined the effects of hGAPDH (2-32) on
chemokine secretion and TLR4 expression of oral epithelial
cells. In previous studies, it has been shown that neutrophil
defensins increased the secretion of IL-8 by pneumocyte-like
A549 and primary bronchial epithelial cells (van Wetering
et al., 2002; Sakamoto et al., 2005). The increased epithelial
expression of IL-8, GM-CSF, and TLR4 of infected epithelial
cells induced by hGAPDH (2-32) in the present study supports
the important role of human antimicrobial peptides for
mucosal immunity by recruitment of activated leukocytes
and lymphocytes to the site of oral infection. In addition, we
demonstrated increased secretion of both cytokines and
mRNA TLR4 expression by hGAPDH (2-32) also of uninfected
epithelial cells compared with the PBS-treated controls.
Recently, we demonstrated the important role of a PMN-
mediated upregulation of epithelial TLR4 for protecting the
oral mucosal surface from fungal invasion and cell injury
(Weindl et al., 2007). Upregulation of TLR4 also in the
absence of PMNs suggests an immune conditioning mechan-
ism by this peptide for host defense. An important role of
hGAPDH (2-32)-induced immunomodulatory effects for tissue
protection is suggested by the observation that epithelial
damage in our infection experiments was significantly reduced
in the presence of 5mg ml1 hGAPDH (2-32), whereas the same
concentration was not very effective in our killing assay.
In this study, we demonstrate that the antimicrobial
peptide hGAPDH (2-32) is secreted by epithelial cells during
mucosal candidiasis. The peptide has a high binding affinity
to the fungal cell wall and may induce apoptosis after inter-
nalization. It partially antagonizes Sap activity, modulates the
immune response, and causes profound changes in the yeast
ultrastructure in vitro. The therapeutic relevance of these
effects during C. albicans infection is confirmed by a strong
protection against tissue damage in an established model of
oral candidiasis. These data imply a protective role for the
antimicrobial peptide hGAPDH (2-32) during experimental
oral candidiasis.
In summary, antimicrobial agents not only acting against
microorganisms in a classical way by fungicidal mechanisms
but also interfering as apoptotic, antivirulence, and immu-
nomodulating drugs are a promising approach to antimicro-
bial therapy.
MATERIALS AND METHODS
Experimental strategy to find antimicrobial peptides
To detect antimicrobial peptides, a peptide library from human
placental tissue was prepared. The collected fractions were
initially screened for growth-inhibitory activity against E. coli as
described previously (Liepke et al., 2003). A fraction demonstrating
antibacterial activity was selected for further purification and
analyzed until the active compound was identified. The synthesized
peptide was used for further testing of antimicrobial activity
against C. albicans. In addition, we tested the inhibitory activity
against Saps and the therapeutic and immunomodulatory effects after
infection of epithelial monolayers and in an in vitro model of oral
candidiasis.
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Preparation of the peptide library
Human placental tissue was obtained from healthy individuals in a
maternity ward of a local hospital after informed written consent. The
design of the work has been approved by the local ethics committee
(ethics committee of Hannover Medical School), and the study was
conducted according to the Declaration of Helsinki Principles. The
tissue was processed immediately after delivery and extracted in ice-
cold 0.5 M acetic acid containing 10 mM ascorbate and 0.5 mM EDTA.
The extract was homogenized, filtered, and subsequently ultrafiltered
as described previously (Liepke et al., 2003). After cation-exchange
chromatography, further subfractioning of each pH pool was carried
out by reversed-phase chromatography (Liepke et al., 2003). Using
this procedure, 42 fractions of each pool were lyophilized and stored
at 20 1C, designated the peptide library.
Purification of antimicrobial peptides from human placental
tissue
Peptides were analyzed by electrospray mass spectrometry and by
capillary zone electrophoresis. Amino-acid sequencing was per-
formed by Edman degradation (Liepke et al., 2003). Each purification
step was monitored by the radial diffusion assay for detection of
antimicrobial activity.
Peptide synthesis
The identified peptide hGAPDH (2-32) was synthesized using Fmoc
solid-phase chemistry on a preloaded TentaGel F-PHB histidine TRT
resin (Rapp Polymere, Tu¨bingen, Germany) and was purified by
reversed-phase HPLC (Vydac C18, 10 mm, 300˚ , gradient: 10–70% B
in 30 minutes, eluent A: 0.07 % trifluoroacetic acid/water, eluent B:
0.05% trifluoroacetic acid in acetonitrile/water 4:1, flow rate:
0.8 ml minute1, UV detection: 215/230 nm). Purity and identity of
synthesized peptides were checked by analytical HPLC, mass
spectrometry, and sequence analysis.
Microorganisms
For our antimicrobial experiments, we used E. coli ATCC 25922 and
the clinical C. albicans isolate SC5314 (Gillum et al., 1984). C.
albicans strains 143 and 526 were isolated from feces, and strain 277
from tracheal secretions and provided by the Institute of Laboratory
Medicine, Klinik am Eichert (Go¨ppingen, Germany).
Antimicrobial assays
Flow cytometric antimicrobial assay measuring membrane depolar-
ization of E. coli ATCC 25922 and fungi was carried out as described
elsewhere (Nuding et al., 2006; Schroeder et al., 2011). Briefly,
1.5 106 cells of E. coli, and the C. albicans strains 143, 277, 526,
and SC5314 were incubated in 1:6 diluted Schaedler broth at 37 1C
with hGAPDH (2-32) in a final volume of 50 ml. The antimicrobial
peptides hGAPDH (2-32), hBD-3 (Peptide Institute, Osaka, Japan), or
LL-37 (Innovagen, Lund, Sweden) were dissolved in 0.01% acetic
acid and added to bacterial and fungal suspensions at 10 mg ml1. To
determine concentration dependence of microbial killing, hGAPDH
(2-32) was added in concentrations of 5, 10, 50, 100, and
125mg ml1. Microbial suspensions incubated with solvent (0.01%
acetic acid) served as controls for viability. After 90 minutes, the
suspensions were incubated for 10 minutes with 1 mg ml1 of the
membrane potential–sensitive dye DiBAC4(3) (Invitrogen, Karlsruhe,
Germany). Suspensions were centrifuged for 10 minutes at 4,500 g,
and the sediments were resuspended in 300 ml PBS. The
percentage of depolarized fluorescent bacteria or fungi in
suspension was determined by a FACSCalibur flow cytometer
(BD, San Jose, CA) using the Cell Quest software (BD) for 10,000
events per sample.
Electron microscopy
Approximately 106 C. albicans SC5314 cells per ml were treated
with hGAPDH (2-32) peptide in a concentration of 125mg ml1 and
incubated for 24 hours at 37 1C. Treated and untreated yeast cells as
a control were centrifuged, and the pellet was fixed in a PBS (0.05 M,
pH 7.3) with 2.5% glutaraldehyde and 2% formaldehyde following
standard methods. Postfixation was carried out with 1% osmium
tetroxide in 0.1 M phosphate buffer at pH 7.3 at room temperature,
and the specimens were embedded in glycid ether. Ultrathin
sections, 20–30 nm thick, were mounted on uncoated copper grids
and stained in 2% uranyl acetate for 3 minutes and examined using a
Zeiss LIBRA transmission electron microscope (Oberkochen, Germany).
Sap inhibition assay
We used recombinant Sap1, Sap2, and Sap3 proteins expressed in
P. pastoris to evaluate the inhibitory activity of hGAPDH (2-32) against
single Sap isoenzymes. We incubated 0.25mg of the indicated Sap
protein with the increasing hGAPDH (2-32) peptide at nonpermissive
pH 7.4 for 1 hour at room temperature in a 40-ml reaction volume. The
Sap proteolytic reaction was then initiated by addition of substrate
(BSA, 8 mg ml1) and pH shift to permissive pH 3.2 in a final volume
of 100ml (peptide/antibody concentration was calculated relative to
the 100ml final volume). The reaction was incubated for 30 minutes at
37 1C and stopped by addition of trichloroacetic acid. Trichloroacetic
acid–soluble peptides were extracted and quantified using the
bicinchoninic acid protein quantification kit from Thermo Scientific
(Bonn, Germany) according to the manufacturer’s indications. Error
bars indicate range of duplicates. Each duplicate consists of three
background-normalized measures.
Generation and affinity purification of the hGAPDH-peptide
antibody
The antigenic peptide GKVKVGVNGFGRIGRLVTRAAFNSGKVDIVA
hGAPDH (2-32) was synthesized on a multiple peptide synthesizer,
Syro II (MultiSynTech, Witten, Germany), using the Fmoc-chemistry.
The peptide was purified using reversed-phase HPLC to 490%
purity, and the identity was confirmed using MALDI-MS-TOF analysis.
The peptide was coupled to keyhole limpet hemocycanin using the
glutardialdehyde method. The obtained antiserum was further purified
by affinity chromatography on a CH-activated Sepharose 4B column
(GE healthcare, Munich, Germany) containing the peptide immobi-
lized via a stable peptide bond (Zaidi et al., 2007). After concen-
tration on a 20-kDa membrane, the resulting antibody was tested by
ELISA on a microplate coated with GAPDH or the peptide hGAPDH
(2-32). For control, the preimmune serum was used.
Analyses of apoptotic and necrotic markers
C. albicans cultures were grown overnight in YPD (yeast extract/
peptone/dextrose) by shaking at 37 1C. A total of 1 107 cells in
250ml PBS were treated with 5mg ml1 hGAPDH (2-32) at 371 for
60 minutes or with 50 mmol H202 as a positive control. After
centrifugation, cells were protoplasted by digesting with SCE
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(sorbitol/sodium-citrat/EDTA) buffer containing 100–500 U mg1
Lyticase from Arthrobacter luteus (Sigma, Taufkirchen, Germany)
and 2-mercaptoethanol (Roth, Karlsruhe, Germany) at 37 1C for
70 minutes. Samples were stained with FITC-labeled annexin-V (BD
Pharmingen, Heidelberg, Germany) and propidium iodide (Mole-
cular Probes, Darmstadt, Germany) to assess the externalization of
phosphatidylserine and cell integrity. Cells were analyzed under a
Leica TCS-SP/Leica DM RB confocal laser scanning microscope
(Leica Microsystems, Wetzlar, Germany) with the Leica Confocal
Software LCS (version 2.61).
Cytokine analysis
GM-CSF and IL-8 concentrations in the culture supernatants were
determined using commercially available ELISA Kits (DuoSet, R&D
Systems Minneapolis, MN).
RNA isolation and quantitative reverse transcriptase–PCR
Total RNA was extracted with NucleoSpin RNAII (Macherey-Nagel,
Du¨ren, Germany) and cDNA was synthesized using 1 mg total RNA
with SuperScript III Reverse Transcriptase (Invitrogen). Amplification
of cDNA was performed as described previously (Weindl et al.,
2007). All samples were run in duplicates and the mean threshold
cycle (Ct) reading was used. Fold difference in gene expression was
normalized to the housekeeping gene (Weindl et al., 2007).
Models of oral candidiasis
For monolayer infection studies, the human buccal cell line TR146
was used. Cells were cultured in DMEM medium with 10% FCS and
0.1% gentamicin solution (50 mg ml1) at 37 1C in 5% CO2.
Infection studies (multiplicity of infection 0.1) were performed in
antibiotic- and antimycotic-free culture medium. Epithelial mono-
layers were infected with C. albicans SC5314 in the presence and
absence of 5, 10, 50, 100, and 125 mg ml1 hGAPDH (2-32) for 12
and 24 hours. To evaluate tissue damage during infection, LDH
analysis was performed (Weindl et al., 2007).
The in vitro model of oral candidiasis was based on multilayer
RHE. The mucosa equivalent and all culture media were prepared as
described previously (Weindl et al., 2007). Epithelial cultures were
infected with 2 106 C. albicans SC5314 cells in 50 ml medium
(3 g l1 tryptic soy broth in 10 mM sodium phosphate buffer, pH 7.2)
containing 5, 10, 50, 100, 125mg ml1 hGAPDH (2-32) or without
peptide as a control. Infected cultures were incubated for 12 and
18 hours at 37 1C in a 100% humidified atmosphere containing 5%
CO2. To evaluate histological changes during infection, light
microscopic studies were carried out as described previously
(Weindl et al., 2007). Histological changes of the mucosa were
evaluated on the basis of 50 sections from five different sites for each
infected epithelium.
For confocal microscopy, oral RHE was cryofixed in liquid
nitrogen, and 5-mm sections were placed on Roti-Bond adhesion
slides (Roth GmbH, Karlsruhe, Germany). Sections were fixed in
periodate–lysine–paraformaldehyde (paraformaldehyde and lysine in
PBS) for 2 minutes, followed by incubation with PBS for 5 minutes,
PBS/BSA (0.1%) plus Tween 20 (0.1%) for 5 minutes, and PBS plus
10% donkey serum for 30 minutes at room temperature. Anti-
hGAPDH (2-32) polyclonal rabbit antibodies (1:50) and human anti-
C. albicans serum (1:60; Virion\Serion, Wu¨rzburg, Germany) were
added for 60 minutes at room temperature. Sections were then
incubated with donkey anti-rabbit–Dylight 549 (1:800; Dianova,
Hamburg, Germany) and donkey anti-human–Cy5 (1:500; Dianova)
for 60 minutes. All nuclei were stained with YOPRO (Invitrogen). All
washing and antibody addition steps were performed with a
combination of PBS, BSA, and Tween. The sections were analyzed
with a confocal laser scanning microscope (Leica TCS SP; Leica
Microsystems) at  400 and  250 magnification.
Statistics
All experiments were performed at least three times, if not otherwise
indicated, and revealed comparable results. Results are presented as
mean±SD. Statistical significance was determined using the two-
tailed paired Student’s t test. A P-value of 0.05 or less was considered
significant.
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